AIM: To generate novel tumor models for preclinicalvalidation of biomarkers that allow drug response prediction and individual therapeutic decisions.METHODS: Cell line establishment was conducted by both direct in vitro culturing and in vivo xenografting followed by in vitro culturing procedure.A comprehensive characterization was subsequently performed.This included quality control,consisting of the confirmation of human and colorectal cancer(CRC) origin by DNA fingerprint and epithelial cell adhesion molecule(EpC AM) staining,as well as mycoplasma and human virus testing.Phenotypic analysis was done by light microscopy and multicolor flow cytometry.Histopathological examination(β-catenin and cytokeratin staining) was conducted in direct comparison to parental tumor tissues.Extensive molecular-pathological profiling included mutation analysis for CRC-associated driver mutations,assessment of chromosomal and microsatellite instability,and the grade of CpG island methylation.Additionally,an arraybased comparative genomic hybridization analysis was performed.Drug responsiveness was assessed for a panel of classical and novel substances in clinical use for the treatment of solid cancers.Finally,tumorigenicity of the cell lines was tested by xenografting into immunocompromised nude mice.RESULTS: Herein we describe the establishment of three ultra-low passage cell lines from two individual patients suffering from sporadic CRC.One cell line was derived directly from an early stage case(HROC18),whereas two cell lines could be established both direct from patient material and after xenografting from a late stage tumor(HROC32).All cell lines were free of contaminating mycoplasma and viruses.Molecularpathological analysis allowed all cell lines to be classified as chromosomal instable(CIN+).They were aneuploid,with CpG island promoter methylation and microsatellite instability being absent.The following mutational profile was observed both in the cell lines and the parental tumor tissue: HROC18: APCmut,p53 mut,K-raswt; HROC32:APCwt,p53 mut,K-rasmut.All cell lines were characterized as epithelial(EpC AM+) cells,showing distinct morphology and migration speed,but comparable growth kinetics.The cell lines showed different patterns of response towards clinically approved and novel drugs,with HROC18 being more resistant than HROC32 cells.Finally,in vivo tumorigenicity was demonstrated.CONCLUSION: We successfully established and characterized novel ultra-low passage patient-derived CRC models as useful instruments for analyzing biological characteristics associated with the CIN+ phenotype. AIM: To generate novel tumor models for preclinicalvalidation of biomarkers that allow drug response prediction and individual therapeutic decisions. METHODS: Cell line establishment was conducted by both direct in vitro culturing and in vivo xenografting followed by in vitro culturing procedure. A comprehensive characterization succeeded composed.This included quality control, consisting of the confirmation of human and colorectal cancer (CRC) origin by DNA fingerprint and epithelial cell adhesion molecule (EpC AM) staining, as well as mycoplasma and human virus testing. Phenotypic analysis was done by light microscopy and multicolor flow cytometry. Histopathological examination (β-catenin and cytokeratin staining) was conducted in direct comparison to parental tumor tissues. Extensive molecular-pathological profiling included mutation analysis for CRC-associated driver mutations, assessment of chromosomal and microsatellite instability, and the grade of CpG island methylation.Additional ly, an array based comparative genomic hybridization analysis was performed. Drug responsiveness was assessed for a panel of classical and novel substances in clinical use for the treatment of solid cancers. Finaally, tumorigenicity of the cell lines was tested by xenografting into immunocompromised nude mice. : Herein we describe the establishment of three ultra-low passage cell lines from two individual patients suffering from sporadic CRC. One cell line was derived directly from an early stage case (HROC18), while two cell lines could be both both from from patient material and after xenografting from a late stage tumor (HROC32). All cell lines were free of contaminating mycoplasma and viruses. Molecular biological analysis of all cell lines to be classified as chromosomal instable (CIN +). They were aneuploid, with CpG island promoter methylation and microsatellite instability being absent.The following mutational profile was observed both in the cell lines and the parental tumor tissue: HROC18: APCmut, p53 mut, K-raswt; HROC32: APCwt, p53 mut, K-rasmut. All cell lines were characterized as epithelial (EpC AM +) cells, showing distinct morphology and migration speed, but comparable growth kinetics. The cell lines showed different patterns of response towards clinically approved and novel drugs, with HROC18 being more resistant than HROC32 cells. Finaally, in vivo tumorigenicity was tested. CONCLUSION: We successfully established and characterized novel ultra-low passage patient-derived CRC models as useful instruments for analyzing biological characteristics associated with the CIN + phenotype.